RFG Advisory’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $12.9M | Buy |
10,775
+1,739
| +19% | +$1.78M | 0.2% | 69 |
|
|
2026
Q1 | $8.31M | Sell |
9,036
-1,394
| -13% | -$1.41M | 0.15% | 102 |
|
|
2025
Q4 | $11.2M | Sell |
10,430
-1,948
| -16% | -$1.86M | 0.21% | 74 |
|
|
2025
Q3 | $9.44M | Buy |
12,378
+756
| +7% | +$563K | 0.2% | 89 |
|
|
2025
Q2 | $9.06M | Sell |
11,622
-351
| -3% | -$273K | 0.21% | 81 |
|
|
2025
Q1 | $9.89M | Buy |
11,973
+1,761
| +17% | +$1.47M | 0.27% | 60 |
|
|
2024
Q4 | $7.88M | Buy |
10,212
+1,206
| +13% | +$999K | 0.22% | 79 |
|
|
2024
Q3 | $7.98M | Buy |
9,006
+635
| +8% | +$571K | 0.24% | 70 |
|
|
2024
Q2 | $7.58M | Buy |
8,371
+1,871
| +29% | +$1.5M | 0.25% | 69 |
|
|
2024
Q1 | $5.06M | Buy |
6,500
+197
| +3% | +$140K | 0.17% | 100 |
|
|
2023
Q4 | $3.67M | Buy |
6,303
+287
| +5% | +$168K | 0.14% | 114 |
|
|
2023
Q3 | $3.23M | Buy |
6,016
+1,436
| +31% | +$740K | 0.14% | 113 |
|
|
2023
Q2 | $2.15M | Buy |
4,580
+313
| +7% | +$131K | 0.1% | 156 |
|
|
2023
Q1 | $1.47M | Buy |
4,267
+49
| +1% | +$16.5K | 0.07% | 202 |
|
|
2022
Q4 | $1.43M | Sell |
4,218
-906
| -18% | -$321K | 0.07% | 209 |
|
|
2022
Q3 | $1.88M | Buy |
5,124
+549
| +12% | +$174K | 0.11% | 154 |
|
|
2022
Q2 | $1.38M | Buy |
4,575
+232
| +5% | +$69.6K | 0.08% | 185 |
|
|
2022
Q1 | $1.24M | Buy |
4,343
+267
| +7% | +$68.7K | 0.08% | 176 |
|
|
2021
Q4 | $1.13M | Buy |
4,076
+596
| +17% | +$151K | 0.08% | 176 |
|
|
2021
Q3 | $804K | Buy |
3,480
+69
| +2% | +$17K | 0.07% | 203 |
|
|
2021
Q2 | $783K | Sell |
3,411
-371
| -10% | -$74.5K | 0.07% | 201 |
|
|
2021
Q1 | $707K | Sell |
3,782
-139
| -4% | -$27.2K | 0.08% | 203 |
|
|
2020
Q4 | $653K | Sell |
3,921
-48
| -1% | -$7.17K | 0.09% | 202 |
|
|
2020
Q3 | $587K | Buy |
3,969
+478
| +14% | +$74K | 0.08% | 208 |
|
|
2020
Q2 | $573K | Buy |
3,491
+338
| +11% | +$51.9K | 0.09% | 189 |
|
|
2020
Q1 | $437K | Sell |
3,153
-134
| -4% | -$18.4K | 0.08% | 197 |
|
|
2019
Q4 | $432K | Sell |
3,287
-430
| -12% | -$49.8K | 0.07% | 217 |
|
|
2019
Q3 | $416K | Buy |
3,717
+632
| +20% | +$70.4K | 0.08% | 186 |
|
|
2019
Q2 | $340K | Buy |
3,085
+425
| +16% | +$50K | 0.08% | 212 |
|
|
2019
Q1 | $344K | Buy |
2,660
+348
| +15% | +$42.3K | 0.09% | 184 |
|
|
2018
Q4 | $268K | Sell |
2,312
-833
| -26% | -$93.1K | 0.07% | 205 |
|
|
2018
Q3 | $337K | Buy |
+3,145
| New | +$314K | 0.09% | 204 |
|
Other funds holding LLY
RFG Advisory's LLY Position: Q2 2026 in Review
RFG Advisory increased its Eli Lilly (LLY) stake by 19% in Q2 2026, buying an estimated $1.78M and bringing the position to 10,775 shares worth $12.9M. The position accounts for 0.2% of the portfolio, ranked #69.
RFG Advisory first reported a position in LLY in Q3 2018 and has held it in 32 quarters since. 4,602 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- RFG Advisory held 10,775 shares of Eli Lilly worth $12.9M as of Q2 2026.
- RFG Advisory bought 1,739 Eli Lilly shares in Q2 2026, an estimated $1.78M.
- Eli Lilly made up 0.2% of RFG Advisory's portfolio in Q2 2026, its #69 holding.
- RFG Advisory first reported a position in Eli Lilly in Q3 2018 and has held it in 32 quarters since.
- 4,602 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on RFG Advisory's 13F filing for Q2 2026, filed 15 Jul 2026.